CoV Biotechnology
CoV Biotechnology is a privately held, early-stage Singapore-based biotechnology company founded in 2022, focused on research into the evolving and mutating nature of the coronavirus.
- Company typePrivate
- Founded1997
- HeadquartersSingapore, Singapore
- Headcount1–10
- GTM typeB2B
- OfferingServices
What CoV Biotechnology does
CoV Biotechnology is a privately held, early-stage biotechnology company founded in 2022 and domiciled in Singapore. Per the available input, the company's stated focus is on the evolving and mutating nature of the coronavirus, suggesting a research orientation around viral evolution, surveillance, or therapeutic/vaccine adaptation, though no specific product candidates, modalities (e.g., mAb, vaccine, small molecule, diagnostic), target indications, or scientific publications are disclosed in the provided data.
The company operates with a minimal team of 1-10 employees based in Singapore. There is no disclosed leadership team, scientific advisory board, management roster, subsidiary structure, or geographic footprint beyond the Singapore headquarters. No patents, trademarks, regulatory actions, partnerships, mergers, acquisitions, or restructuring events are recorded for the company in the input. The website (covbiotech.com) is the only public-facing asset referenced.
On the commercial side, no customers, pricing, revenue, or revenue model are disclosed. The single capital event on record is a funding round dated 2022-09-16 with Polaris Partners as investor (round amount logged as $0, implying undisclosed rather than nominal). No subsequent funding rounds, institutional backers, or grant funding are referenced. As a result, the company should be understood as a pre-revenue, founder-stage biotech with one named institutional investor and a single stated research theme; substantial further disclosure would be required to characterize pipeline, burn rate, runway, or scientific differentiation.
CoV Biotechnology firmographics
Firmographics- Name
- CoV Biotechnology
- Legal name
- System Overdrive Pte Ltd
- Website
- https://covbiotech.com
- Company type
- Private
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CoV Biotechnology is a privately held, early-stage Singapore-based biotechnology company founded in 2022, focused on research into the evolving and mutating nature of the coronavirus.
- Ownership category
- akta.pro rank
CoV Biotechnology industry classification
Industry- Product category
- Biotechnology Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industry
- Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)
Keywords
Where CoV Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices6 records
Markets served
CoV Biotechnology business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Managed IT Services: Comprehensive IT services including 24/7 monitoring, support, proactive issue detection, system health checks, and asset lifecycle management. Generates recurring revenue through ongoing service contracts.
- Cloud Solutions: Cloud readiness assessments, secure data migration, Microsoft 365 implementation, and hybrid infrastructure design. Revenue from consulting and implementation services.
- AI & Custom Software Development: Custom AI solutions including LLM applications, OCR systems, predictive analytics, and custom ERP/CRM development. One-time development projects and potentially ongoing maintenance contracts.
- IT Hardware & Software Resale: Value-Added Reseller for IT hardware and software including partnerships with Microsoft, HP, IBM, Dell, and others. Revenue from product sales and licensing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise solutions with quote-based pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
CoV Biotechnology product offering
Product offeringCore offering
CoV Biotechnology is an early-stage biotechnology company that conducts research and development focused on the evolving and mutating nature of the coronavirus. The company works in the infectious disease biotechnology space, targeting viral mutation analysis and coronavirus biology.
Product overview
System Overdrive is an AI enablement company offering a portfolio of integrated technology solutions. The core offerings consist of three main solution areas: (1) Artificial Intelligence Solutions providing production-grade AI for OCR, Machine Vision, LLM applications, and time-series forecasting; (2) Cloud Infrastructure Services as a certified provider for AWS, Azure, and Alicloud; and (3) Business Applications including ERP (Odoo), CRM, KPI dashboards, and workflow automation. These are complemented byManaged IT Services for ongoing infrastructure support and AI & Custom Software Development for bespoke solutions. The company positions itself as a one-stop AI strategy and implementation partner serving enterprises across Southeast Asia.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Trusted by 300+ businesses across Southeast Asia
- +1 more outcomes
Companies that use CoV Biotechnology
Customer profileSegments6 records
CoV Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature9 records
CoV Biotechnology partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and minor.
- MicrosoftcoreMicrosoft Silver Partner status achieved in 2010. Certified Cloud Solution Provider for Microsoft 365 and Azure cloud services. Partnership enables delivery of Microsoft-centric enterprise solutions including Microsoft 365 rollouts, Azure cloud infrastructure, and related professional services.
- AWScoreAWS Cloud Solution Provider since 2010, enabling AWS cloud migration and infrastructure services. Certified partnership for delivering AWS-based enterprise solutions across Southeast Asia.
- AzurecoreAzure Cloud Solution Provider since 2010, part of the multi-cloud strategy. Enables delivery of Microsoft Azure-based cloud solutions alongside AWS and Alicloud offerings.
- AlicloudcoreAlicloud Cloud Solution Provider since 2010, completing the multi-cloud portfolio. Provides flexibility for customers requiring Alibaba Cloud infrastructure solutions.
- OdoocoreStrategic partnership for ERP implementation using Odoo platform since 2010. Enables customized ERP solutions for enterprise customers including CRM, KPI dashboards, and workflow automation.
- LenovominorValue-Added Reseller for Lenovo hardware solutions. Expands the hardware portfolio available to enterprise customers.
- Trend MicrominorSecurity solutions partnership for Trend Micro enterprise security products. Provides additional security offerings for cloud and hybrid infrastructure deployments.
- HPcoreValue-Added Reseller partnership established in 2006 for IT hardware including HP enterprise equipment. Part of the company's hardware and software resale business model.
- DellcoreValue-Added Reseller partnership established in 2006 for Dell IT hardware and solutions. Enables enterprise hardware procurement and deployment services.
- IBMminorPartnership established in 2006 for IBM hardware and software solutions. Contributed to early revenue growth achieving SGD 1M+ milestone.
- SymantecminorSecurity software resale partnership established in 2006. Provided endpoint and data security solutions to enterprise customers.
Scale indicators5 records
Recent moves2 records
Expansion highlights3 records
CoV Biotechnology competitors and assessment
Company assessmentBroad incumbents
- Vir Biotechnology: Clinical-stage immunology company with a leading COVID-19 antibody (sotrovimab) and a broader infectious-disease pipeline. Comparable as a coronavirus-focused biotech, though materially larger and further along commercially.
- Moderna: Commercial-stage mRNA platform company whose COVID-19 vaccine (Spikevax) defined the pandemic era. Relevant as the dominant scale player in coronavirus countermeasure development against which smaller entrants must differentiate.
- BioNTech: Commercial-stage immunotherapy company co-developer of the Pfizer-BioNTech COVID-19 vaccine. Comparable as a leading coronavirus countermeasure developer with significant R&D resources and global commercial reach.
- Regeneron Pharmaceuticals: Large-cap biotech with an approved COVID-19 antibody therapy (REGEN-COV/ronapreve). Comparable as a major countermeasure developer, though its focus and scale extend well beyond coronavirus.
Emerging players
- Sherlock Biosciences: Molecular diagnostics company with CRISPR-based infectious-disease tests including COVID detection. Comparable as a smaller, venture-backed infectious-disease platform intersecting diagnostics and pandemic response.
- Cue Health: Molecular diagnostics company that built a connected COVID-19 test platform. Comparable as a venture-stage infectious-disease diagnostics peer, though larger and more commercially established.
- Pardes Biosciences: Early-to-mid-stage biotech developing oral antivirals against coronaviruses. Comparable to CoV Biotechnology in being a younger, venture-backed coronavirus-focused biotech, though more advanced on the therapeutic side.
- Aerium Therapeutics: Early-stage antiviral biotech with a stated focus on pandemic preparedness and coronaviruses. Closest comparable in stage and orientation — small, venture-backed, broad coronavirus therapeutic scope.
Market position
Strengths4 records
Weaknesses4 records
Key risks5 records
Key highlights4 records
Customer concentration
CoV Biotechnology compliance and trust
Trust signalCompliance3 records
CoV Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
CoV Biotechnology leadership team
Management profileNumber of profiles
CoV Biotechnology funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CoV Biotechnology M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CoV Biotechnology
What does CoV Biotechnology do?
CoV Biotechnology is an early-stage biotechnology company that conducts research and development focused on the evolving and mutating nature of the coronavirus. The company works in the infectious disease biotechnology space, targeting viral mutation analysis and coronavirus biology.
Is CoV Biotechnology a public or private company?
CoV Biotechnology is a private company. It is classified as venture growth investor backed and is currently operating.
When was CoV Biotechnology founded?
CoV Biotechnology was founded in 1997. It employs 1 to 10 people.
Where is CoV Biotechnology based?
CoV Biotechnology is headquartered in Singapore, Singapore, in the Asia region.
How does CoV Biotechnology make money?
Four revenue lines are on record. Managed IT Services are the primary driver. The others are cloud Solutions, AI & Custom Software Development and IT Hardware & Software Resale.
Who are CoV Biotechnology's main competitors?
Broad incumbents on record are Vir Biotechnology, Moderna, BioNTech and Regeneron Pharmaceuticals. Emerging players are Sherlock Biosciences, Cue Health, Pardes Biosciences and Aerium Therapeutics.
Does CoV Biotechnology have an API?
No public API is recorded for CoV Biotechnology.
What industry is CoV Biotechnology in?
CoV Biotechnology's product category is Biotechnology Research. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAAMAB, Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy). Its NAICS code is 541714 and its SIC code is 2835.